News

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its

Are we witnessing the rise of a new biotech giant? A few weeks ago, Viking Therapeutics (NASDAQ: VKTX) grabbed headlines when it reported positive results from a phase 2 clinical trial for VK2735, a

Viking Therapeutics (NASDAQ: VKTX) is on a tear this year, with shares catapulting upward by 340% thanks to good data (and high expectations) from one of its mid-stage clinical trials testing a

What's the most important ingredient for investing successfully? Time. However, some stocks require much less time to deliver huge returns than others.

You may have to be patient for significant

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have seen their revenue soar in recent times thanks to their weight loss drugs. The companies sell products that target key hormones involved in

Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about

Sometimes it is worth it to buy shares of companies on the dip, and sometimes it isn't. It all depends on whether there are good reasons to believe the company in question will bounce back, and if

There aren't many hotter stocks on the market right now than Viking Therapeutics (NASDAQ: VKTX). Shares of the biopharmaceutical company have skyrocketed around 340% so far this year.

However, those

Investors looking for stocks that can make dramatic gains in a short time frame might want to turn their attention to the biopharmaceutical industry. Shares of Viking Therapeutics (NASDAQ: VKTX)

No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as

No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as

A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer

A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer

One of the biggest tailwinds in the pharmaceutical industry is weight loss treatments. Breakthroughs in semaglutide and tirzepatide have given rise to several glucagon-like peptide-1 (GLP-1)

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while

2024 is off to a great start for many investors, with the S&P 500 climbing 10.2% in the first quarter, roughly the performance the index averages for an entire year. Since the end of 2022, the S&P

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.

Three Motley Fool contributors believe they've identified three

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.

Three Motley Fool contributors believe they've identified three

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.

Three Motley Fool contributors believe they've identified three

Shares of Novocure (NASDAQ: NVCR) jumped 18.3% this week, according to data from S&P Global Market Intelligence, after the company announced encouraging results from a phase 3 study of its Tumor

Viking Therapeutics (NASDAQ: VKTX) has emerged this year as a formidable contender in the increasingly popular anti-obesity market. While it doesn't have an approved drug fighting for market share

Relatively small biotechs can see their shares soar -- sometimes significantly -- following positive clinical or regulatory news.

That's what has happened this year to Viking Therapeutics (NASDAQ: